SP-624

DRUG4 trials

Sponsors

Sirtsei Pharmaceuticals, Inc.

Conditions

DepressionHealthyMajor Depressive DisorderSchizophrenia

Phase 1

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

CompletedNCT04510298

Sirtsei Pharmaceuticals, Inc.Schizophrenia

Start: 2020-10-15End: 2021-04-15Updated: 2022-04-25

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

CompletedNCT06570369

Sirtsei Pharmaceuticals, Inc.Depression, Healthy, Major Depressive Disorder

Start: 2024-08-22End: 2026-05-18Updated: 2026-05-28

Phase 2

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

CompletedNCT04479852

Sirtsei Pharmaceuticals, Inc.Major Depressive Disorder

Start: 2020-09-30End: 2022-08-09Updated: 2025-06-12

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

CompletedNCT06254612

Sirtsei Pharmaceuticals, Inc.Major Depressive Disorder

Start: 2024-03-25End: 2026-07-08Updated: 2026-08-18

Related Papers

A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder

Current Medical Research and Opinion2025-09-02